Korro Bio
KRRO
75 hedge funds and large institutions have $169M invested in Korro Bio in 2025 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 22 increasing their positions, 25 reducing their positions, and 18 closing their positions.
2.53% more ownership
Funds ownership: 100.82% → 103.35% (+2.5%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
11% less funds holding
Funds holding: 84 → 75 (-9)
12% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 25
50% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 18
53% less capital invested
Capital invested by funds: $360M → $169M (-$191M)
Top Buyers
Top Sellers
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$4.48M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$3.45M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
-$2.45M |
| 4 |
Verition Fund Management
Greenwich,
Connecticut
|
-$2.36M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$1.54M |
KRRO Hedge Fund Activity: Q1 2025 in Review
75 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Korro Bio (KRRO) for Q1 2025, worth a combined $169M — down 53% from $360M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of KRRO and 9 opened new positions — a net loss of 9 holders — while 25 trimmed existing stakes and 22 added.
The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $11.3M. The largest seller was Eventide Asset Management, exiting entirely with an estimated $4.48M sold.
- 75 institutional investors held Korro Bio (KRRO) as of Q1 2025, down from 84 in Q4 2024.
- Funds reported $169M of Korro Bio stock for Q1 2025, down 53% quarter-over-quarter.
- 9 funds opened new Korro Bio positions in Q1 2025 and 18 closed out, a net change of -9 holders.
- The largest Korro Bio buyer in Q1 2025 was Cormorant Asset Management, an estimated $11.3M added.
- The largest Korro Bio seller in Q1 2025 was Eventide Asset Management, an estimated $4.48M sold.
Based on aggregated 13F filings for Q1 2025.